http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101554574-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6cb4ab729c5c94a203059e5d3f32dbeb |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/H01F1-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J13-02 |
| filingDate | 2009-04-21^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcb3367b1a41829d09662d68577a8e7f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7c6a96a662cd22aae30e1cb2e84092a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dca26688ea79c8b64e56566a4bb484bf |
| publicationDate | 2009-10-14^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-101554574-A |
| titleOfInvention | Superparamagnetism nano particle jointly modified by aminosilane coupling agent and hyskon and preparation method thereof |
| abstract | The invention discloses superparamagnetism nano particle jointly modified by an aminosilane coupling agent and hyskon, and a preparation method thereof. The superparamagnetism nano particle has a core-shell structure; the inner core of the particle is magnetic ferroferric oxide; the surface of the inner core is a hyskon coating layer; and the external surface of the hyskon coating layer is connected with the aminosilane coupling agent. The preparation method comprises the following steps of: firstly preparing the hyskon-coated superparamagnetism ferroferric oxide nano particle; and secondly modifying the surface of the hyskon-coated superparamagnetism ferroferric oxide nano particle by the aminosilane coupling agent. The superparamagnetism nano particle has high hydrophilicity, steadily spreads in water phase, can reduce the phagotrophy quantity of reticulo endothelium, extends cycle time in water, is full with amidogen at the surface thereof, can conveniently combine with monoclonal antibody so as to improve active targeting, causes no toxic side effect to human body, and has good biocompatibility, simple preparation method and good application prospect in the early diagnosis of malignant tumor and the treatment field of targeting. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111041014-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-101693128-B |
| priorityDate | 2009-04-21^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 56 of 56.